Middle East Pharmaceutical Industries Company (TADAWUL:4016)

Market Cap	2.70B
Revenue (ttm)	432.07M
Net Income (ttm)	92.88M
Shares Out	20.00M
EPS (ttm)	4.64
PE Ratio	29.09
Forward PE	25.16
Dividend	2.50 (1.85%)
Ex-Dividend Date	Sep 2, 2025

Volume	37,242
Average Volume	43,211
Open	134.00
Previous Close	135.10
Day's Range	134.00 - 135.50
52-Week Range	108.00 - 140.60
Beta	n/a
RSI	60.77
Earnings Date	Nov 12, 2025

About TADAWUL:4016

Middle East Pharmaceutical Industries Company engages in the research, development, manufacture, and marketing of generic medicines and pharmaceutical preparations in the Kingdom of Saudi Arabia and internationally. The company operates through three segments: Private, Public, and Export. It offers medicines and preparations used to treat skin diseases, skin creams, and skin care products; respiratory, central nervous, digestive, and musculoskeletal system medicines; urinary and reproductive system drugs; disinfectants; and various therapeutic ...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1998
• Employees: 632
• Stock Exchange: Saudi Stock Exchange
• Ticker Symbol: 4016

Financial Performance

In 2024, TADAWUL:4016's revenue was 394.00 million, an increase of 16.42% compared to the previous year's 338.44 million. Earnings were 79.85 million, an increase of 21.30%.